Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting
Abstract
Authors
L Donvovan H Kim